FDA approves ImClone's Erbitux; drug to be available in two weeks

02/13/2004 | Wall Street Journal, The

The FDA gave its approval of ImClone Systems' Erbitux as a treatment for aggressive colon cancer, making it the company's first product to receive federal clearance. The approval came two years after the agency first denied ImClone approval of the drug, a decision that led to responses resulting in the Martha Stewart insider-trading scandal. Bristol-Myers Squibb, co-developer of Erbitux with ImClone, said the drug would be available on the market in two weeks.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC